Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + etomidate
- Development stage
- Unknown
- Lead developer
- AkzoNobel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of propofol and etomidate used primarily for procedural sedation, particularly during gastroscopy and other endoscopic procedures. This combination leverages the complementary properties of both drugs to achieve improved hemodynamic stability with fewer side effects compared to either agent used alone. The mixture maintains cardiovascular stability while providing effective sedation, making it particularly valuable for elderly patients and those with cardiovascular concerns.
- Other names
- Propofol-Etomidate AdmixtureEtomidate-Propofol AdmixturePropofol and Etomidate Admixtures
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on propofol + etomidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + etomidate.